Shopping Cart 0
Cart Subtotal
AED 0

Opiant Pharmaceuticals Inc (OPNT)-Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Opiant Pharmaceuticals Inc (OPNT)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing a treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder (BED), and treatment for cocaine use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant's first product, NARCAN Nasal Spray, is approved for marketing in the US by its partner, Adapt Pharma. The company is also developing opioid antagonists with a near term focus on cocaine use disorder, binge eating disorder (BED) and bulimia nervosa. Opiant is headquartered in Santa Monica, California, the US.

Opiant Pharmaceuticals Inc Key Recent Developments

Jun 15,2017: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update

Mar 16,2017: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update

Feb 06,2017: Opiant Pharmaceuticals Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer

Dec 16,2016: Opiant Pharmaceuticals Reports Fiscal First Quarter 2017 Financial Results

Nov 10,2016: Opiant Pharmaceuticals Announces Appointment of Thomas T. Thomas to Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Opiant Pharmaceuticals Inc-Key Facts 6

Opiant Pharmaceuticals Inc-Key Employees 7

Opiant Pharmaceuticals Inc-Key Employee Biographies 8

Opiant Pharmaceuticals Inc-Major Products and Services 9

Opiant Pharmaceuticals Inc-History 10

Opiant Pharmaceuticals Inc-Company Statement 12

Opiant Pharmaceuticals Inc-Locations And Subsidiaries 13

Head Office 13

Section 2-Company Analysis 14

Opiant Pharmaceuticals Inc-Business Description 14

Opiant Pharmaceuticals Inc-Corporate Strategy 15

Opiant Pharmaceuticals Inc-SWOT Analysis 16

SWOT Analysis-Overview 16

Opiant Pharmaceuticals Inc-Strengths 16

Opiant Pharmaceuticals Inc-Weaknesses 17

Opiant Pharmaceuticals Inc-Opportunities 18

Opiant Pharmaceuticals Inc-Threats 19

Opiant Pharmaceuticals Inc-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 24

Financial Performance 24

Financial Ratios-Interim Ratios 25

Financial Ratios-Ratio Charts 26

Section 4-Company's Lifesciences Financial Deals and Alliances 27

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28

Opiant Pharmaceuticals Inc, Recent Deals Summary 29

Section 5-Company's Recent Developments 30

Jun 15, 2017: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update 30

Mar 16, 2017: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update 32

Feb 06, 2017: Opiant Pharmaceuticals Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer 33

Dec 16, 2016: Opiant Pharmaceuticals Reports Fiscal First Quarter 2017 Financial Results 34

Nov 10, 2016: Opiant Pharmaceuticals Announces Appointment of Thomas T. Thomas to Board of Directors 35

Oct 31, 2016: Opiant Pharmaceuticals Reports Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 36

Jun 09, 2016: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2016 Financial Results and Provides Corporate Update 37

May 12, 2016: Opiant Pharmaceuticals Announces Appointments Of Gabrielle A. Silver, M.D., And Ann Macdougall To Board Of Directors 38

Mar 16, 2016: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2016 Financial Results and Provides Corporate Update 39

Mar 07, 2016: Opiant Pharmaceuticals Announces Ticker Symbol Change to "OPNT" 40

Section 6-Appendix 41

Methodology 41

Ratio Definitions 41

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Opiant Pharmaceuticals Inc, Performance Chart (2012-2016) 24

Opiant Pharmaceuticals Inc, Ratio Charts 26

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 28


List Of Table

List of Tables

Opiant Pharmaceuticals Inc, Key Facts 6

Opiant Pharmaceuticals Inc, Key Employees 7

Opiant Pharmaceuticals Inc, Key Employee Biographies 8

Opiant Pharmaceuticals Inc, Major Products and Services 9

Opiant Pharmaceuticals Inc, History 10

Opiant Pharmaceuticals Inc, Key Competitors 20

Opiant Pharmaceuticals Inc, Ratios based on current share price 21

Opiant Pharmaceuticals Inc, Annual Ratios 22

Opiant Pharmaceuticals Inc, Annual Ratios (Cont...1) 23

Opiant Pharmaceuticals Inc, Interim Ratios 25

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28

Opiant Pharmaceuticals Inc, Recent Deals Summary 29

Currency Codes 41

Capital Market Ratios 41

Equity Ratios 42

Profitability Ratios 42

Cost Ratios 43

Liquidity Ratios 43

Leverage Ratios 44

Efficiency Ratios 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Opiant Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

Opiant Pharmaceuticals Inc (OPNT)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing a treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder (BED), and treatment for cocaine use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant's first product, NARCAN Nasal Spray, is approved for marketing in the US by its partner, Adapt Pharma. The company is also developing opioid antagonists with a near term focus on cocaine use disorder, binge eating disorder (BED) and bulimia nervosa. Opiant is headquartered in Santa Monica, California, the US.

Opiant Pharmaceuticals Inc Key Recent Developments

Jun 15,2017: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update

Mar 16,2017: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update

Feb 06,2017: Opiant Pharmaceuticals Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer

Dec 16,2016: Opiant Pharmaceuticals Reports Fiscal First Quarter 2017 Financial Results

Nov 10,2016: Opiant Pharmaceuticals Announces Appointment of Thomas T. Thomas to Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Opiant Pharmaceuticals Inc-Key Facts 6

Opiant Pharmaceuticals Inc-Key Employees 7

Opiant Pharmaceuticals Inc-Key Employee Biographies 8

Opiant Pharmaceuticals Inc-Major Products and Services 9

Opiant Pharmaceuticals Inc-History 10

Opiant Pharmaceuticals Inc-Company Statement 12

Opiant Pharmaceuticals Inc-Locations And Subsidiaries 13

Head Office 13

Section 2-Company Analysis 14

Opiant Pharmaceuticals Inc-Business Description 14

Opiant Pharmaceuticals Inc-Corporate Strategy 15

Opiant Pharmaceuticals Inc-SWOT Analysis 16

SWOT Analysis-Overview 16

Opiant Pharmaceuticals Inc-Strengths 16

Opiant Pharmaceuticals Inc-Weaknesses 17

Opiant Pharmaceuticals Inc-Opportunities 18

Opiant Pharmaceuticals Inc-Threats 19

Opiant Pharmaceuticals Inc-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 24

Financial Performance 24

Financial Ratios-Interim Ratios 25

Financial Ratios-Ratio Charts 26

Section 4-Company's Lifesciences Financial Deals and Alliances 27

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28

Opiant Pharmaceuticals Inc, Recent Deals Summary 29

Section 5-Company's Recent Developments 30

Jun 15, 2017: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update 30

Mar 16, 2017: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update 32

Feb 06, 2017: Opiant Pharmaceuticals Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer 33

Dec 16, 2016: Opiant Pharmaceuticals Reports Fiscal First Quarter 2017 Financial Results 34

Nov 10, 2016: Opiant Pharmaceuticals Announces Appointment of Thomas T. Thomas to Board of Directors 35

Oct 31, 2016: Opiant Pharmaceuticals Reports Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 36

Jun 09, 2016: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2016 Financial Results and Provides Corporate Update 37

May 12, 2016: Opiant Pharmaceuticals Announces Appointments Of Gabrielle A. Silver, M.D., And Ann Macdougall To Board Of Directors 38

Mar 16, 2016: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2016 Financial Results and Provides Corporate Update 39

Mar 07, 2016: Opiant Pharmaceuticals Announces Ticker Symbol Change to "OPNT" 40

Section 6-Appendix 41

Methodology 41

Ratio Definitions 41

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Opiant Pharmaceuticals Inc, Performance Chart (2012-2016) 24

Opiant Pharmaceuticals Inc, Ratio Charts 26

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 28


List Of Table

List of Tables

Opiant Pharmaceuticals Inc, Key Facts 6

Opiant Pharmaceuticals Inc, Key Employees 7

Opiant Pharmaceuticals Inc, Key Employee Biographies 8

Opiant Pharmaceuticals Inc, Major Products and Services 9

Opiant Pharmaceuticals Inc, History 10

Opiant Pharmaceuticals Inc, Key Competitors 20

Opiant Pharmaceuticals Inc, Ratios based on current share price 21

Opiant Pharmaceuticals Inc, Annual Ratios 22

Opiant Pharmaceuticals Inc, Annual Ratios (Cont...1) 23

Opiant Pharmaceuticals Inc, Interim Ratios 25

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28

Opiant Pharmaceuticals Inc, Recent Deals Summary 29

Currency Codes 41

Capital Market Ratios 41

Equity Ratios 42

Profitability Ratios 42

Cost Ratios 43

Liquidity Ratios 43

Leverage Ratios 44

Efficiency Ratios 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Opiant Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

chat_bubbleLet's Chat